Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,237 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Disorder Clear all
Completed Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0600

NCT00512317
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

NCT05081518
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 27, 2026, 4:32 PM EDT
Approved For Marketing No phase listed Expanded access

Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

NCT00918424
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine Extended Release
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Loxahatchee Groves, Florida • Palm Beach, Florida • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 27, 2026, 4:32 PM EDT
Recruiting No phase listed Observational

Recovery Trajectory for Coma and Disorders of Consciousness

NCT07614074
View directory record Official record
Conditions
Coma, Disorders of Consciousness, Cardiac Arrest (CA), Traumatic Brain Injuries, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral, Meningitis/Encephalitis, Status Epilepticus
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00699283
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
43
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 27, 2026, 4:32 PM EDT
Active, not recruiting Not applicable Interventional

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)

NCT05235061
View directory record Official record
Conditions
Epilepsy, Traumatic, Brain Injuries, Traumatic
Interventions
Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE), HOBSCOTCH-PTE for Caregivers
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655551
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Not applicable Interventional

Prevention of Photoparoxysmal Abnormalities by Mozart K448

NCT01363154
View directory record Official record
Conditions
Photoparoxysmal Abnormalities, Epilepsy, Seizures
Interventions
Mozart K448, Beethoven's Für Elise, No music exposure
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Phase 4 Interventional

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

NCT02727101
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 27, 2026, 4:32 PM EDT
Completed No phase listed Observational

A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy

NCT04924153
View directory record Official record
Conditions
KCNT1-Related Epilepsy
Interventions
No Intervention
Other
Lead sponsor
Biogen
Industry
Eligibility
0 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

NCT04625101
View directory record Official record
Conditions
Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Interventions
NBI-827104, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
4 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 27, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 27, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

NCT05996900
View directory record Official record
Conditions
Major Depressive Disorder, Epilepsy
Interventions
Intracranial electrodes, TMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexmedetomidine in Seizure Patients

NCT01116700
View directory record Official record
Conditions
Seizure Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 27, 2026, 4:32 PM EDT
Completed No phase listed Observational

Pediatric Seizure Movement Bed Alarm

NCT01855178
View directory record Official record
Conditions
Seizures, Sleep, Epilepsy
Interventions
Emfit Movement Monitor
Device
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 27, 2026, 4:32 PM EDT
Recruiting Early Phase 1 Interventional

Accelerated TMS for Seizure-Type Functional Neurologic Disorders

NCT07059325
View directory record Official record
Conditions
Functional Neurological Symptom Disorder, Functional Seizures
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 4:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen, Sham Comparator
Drug · Other
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

NCT02332655
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Cannabidiol
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
1 Month to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 27, 2026, 4:32 PM EDT
Completed No phase listed Observational

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

NCT03892798
View directory record Official record
Conditions
Autism Spectrum Disorder, Movement Disorders, Seizures, Dystonia, NEDAMSS
Interventions
No interventions are planned
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Months to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 27, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blast Exposed Veterans With Auditory Complaints

NCT02122458
View directory record Official record
Conditions
Hearing Impairment, Hearing Aid Fitting
Interventions
mild-gain hearing aids with high-frequency emphasis over 6-months
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 50 Years
Enrollment
363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
3
States / cities
Portland, Oregon • Pittsburgh, Pennsylvania • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 27, 2026, 4:32 PM EDT